collection
MENU ▼
Read by QxMD icon Read
search

Achieving Depression Remission

shared collection
124 papers 500 to 1000 followers
By Edwin Kim Resident Physician, Aspiring Addiction Psychiatrist
https://www.readbyqxmd.com/read/15784664/the-serotonin-syndrome
#1
REVIEW
Edward W Boyer, Michael Shannon
No abstract text is available yet for this article.
March 17, 2005: New England Journal of Medicine
https://www.readbyqxmd.com/read/28485261/ten-month-outcome-of-cognitive-behavioural-therapy-v-interpersonal-psychotherapy-in-patients-with-major-depression-a-randomised-trial-of-acute-and-maintenance-psychotherapy
#2
R Mulder, J Boden, J Carter, S Luty, P Joyce
BACKGROUND: Cognitive behaviour therapy (CBT) and interpersonal psychotherapy (IPT) are the most studied psychotherapies for treatment of depression, but they are rarely directly compared particularly over the longer term. This study compares the outcomes of patients treated with CBT and IPT over 10 months and tests whether there are differential or general predictors of outcome. METHODS: A single centre randomised controlled trial (RCT) of depressed outpatients treated with weekly CBT or IPT sessions for 16 weeks and then 24 weeks of maintenance CBT or IPT...
May 9, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28292224/universal-depression-screening-to-improve-depression-outcomes-in-primary-care-sounds-good-but-where-is-the-evidence
#3
Ramin Mojtabai
The 2016 recommendation statement by the U.S. Preventive Services Task Force (USPSTF) endorsed screening for depression in the general adult population. The recommendation was mainly based on studies that compared enhanced depression care that included depression screening with usual care. In contrast to the USPSTF recommendation, the 2013 guidelines from the Canadian Task Force on Preventive Health Care (CTFPHC) recommended against routine depression screening. The CTFPHC could not identify any studies comparing depression outcomes of usual care with and without the addition of routine depression screening...
March 15, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/24524926/change-in-mental-health-after-smoking-cessation-systematic-review-and-meta-analysis
#4
REVIEW
Gemma Taylor, Ann McNeill, Alan Girling, Amanda Farley, Nicola Lindson-Hawley, Paul Aveyard
OBJECTIVE: To investigate change in mental health after smoking cessation compared with continuing to smoke. DESIGN: Systematic review and meta-analysis of observational studies. DATA SOURCES: Web of Science, Cochrane Central Register of Controlled Trials, Medline, Embase, and PsycINFO for relevant studies from inception to April 2012. Reference lists of included studies were hand searched, and authors were contacted when insufficient data were reported...
February 13, 2014: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28448702/ketamine-for-depression-1-clinical-summary-of-issues-related-to-efficacy-adverse-effects-and-mechanism-of-action
#5
Chittaranjan Andrade
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from conventional antidepressant drugs in that it brings about rapid and marked attenuation of depressive symptoms even in patients with refractory depression...
April 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28335624/effects-of-patient-preferences-on-outcomes-in-the-predictors-of-remission-in-depression-to-individual-and-combined-treatments-predict-study
#6
Boadie W Dunlop, Mary E Kelley, Vivianne Aponte-Rivera, Tanja Mletzko-Crowe, Becky Kinkead, James C Ritchie, Charles B Nemeroff, W Edward Craighead, Helen S Mayberg
OBJECTIVE: The Predictors of Remission in Depression to Individual and Combined Treatments [PReDICT] study aimed to identify clinical and biological factors predictive of treatment outcomes in major depressive disorder among treatment-naive adults. The authors evaluated the efficacy of cognitive-behavioral therapy (CBT) and two antidepressant medications (escitalopram and duloxetine) in patients with major depression and examined the moderating effect of patients' treatment preferences on outcomes...
March 24, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26997505/therapeutic-modulation-of-glutamate-receptors-in-major-depressive-disorder
#7
REVIEW
Brittany A Jaso, Mark J Niciu, Nicolas D Iadarola, Niall Lally, Erica M Richards, Minkyung Park, Elizabeth D Ballard, Allison C Nugent, Rodrigo Machado-Vieira, Carlos A Zarate
Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications for MDD act primarily through monoaminergic mechanisms, e.g., receptor/reuptake agonists or antagonists with varying affinities for serotonin, norepinephrine, or dopamine. Glutamate is the major excitatory neurotransmitter in the central nervous system, and glutamate and its cognate receptors are implicated in the pathophysiology of MDD, as well as in the development of novel therapeutics for this disorder...
2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/27738380/treatment-resistant-depression-with-loss-of-antidepressant-response-rapid-acting-antidepressant-action-of-dextromethorphan-a-possible-treatment-bridging-molecule
#8
Edward C Lauterbach
Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.(1,2) This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a rapid-acting antidepressant effect within 48 hours of DM administration and lasting 7 days, sustained up to 20 days with daily administration, then gradually developing labile loss of antidepressant response over the ensuing 7 days...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/17205639/the-expert-consensus-guideline-series-pharmacotherapy-of-depressive-disorders-in-older-patients
#9
G S Alexopoulos, I R Katz, C F Reynolds, D Carpenter, J P Docherty
OBJECTIVES: Depression in older patients contributes to personal suffering and family disruption and increases disability, medical morbidity, mortality, suicide risk, and healthcare utilization. The majority of clinical trials of antidepressant treatments are conducted in younger patients. For this reason, clinicians often have to extrapolate from studies in populations that do not present the same problems as older patients. For example, older patients often have serious coexisting medical conditions that may contribute to the depression and complicate the choice of treatment...
October 2001: Postgraduate Medicine
https://www.readbyqxmd.com/read/28252882/effectiveness-of-supplementary-cognitive-behavioral-therapy-for-pharmacotherapy-resistant-depression-a-randomized-controlled-trial
#10
Atsuo Nakagawa, Dai Mitsuda, Mitsuhiro Sado, Takayuki Abe, Daisuke Fujisawa, Toshiaki Kikuchi, Satoru Iwashita, Masaru Mimura, Yutaka Ono
OBJECTIVE: Antidepressant medication is efficacious in the treatment of depression, but not all patients improve with antidepressant medication alone. Despite this treatment gap, limited evidence regarding the effectiveness of supplementing psychotherapy for pharmacotherapy-resistant depression is available. Therefore, we investigated the effectiveness of supplementing usual medication management (treatment as usual [TAU]) with cognitive-behavioral therapy (CBT) in patients with pharmacotherapy-resistant depression seeking psychiatric specialty care...
February 28, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27816323/association-between-low-serum-25-hydroxyvitamin-d-and-depression-in-a-large-sample-of-chinese-patients-with-type-2-diabetes-mellitus
#11
Yuhong Wang, Hui Yang, Pan Meng, Yuanshan Han
BACKGROUND: Because of the absence of data on the direct association between vitamin D and depression in patients with diabetes, we examined the association between vitamin D state (assessed by 25-hydroxyvitamin D [25(OH)D]) and the prevalence of depression in adult patients with type 2 diabetes mellitus(T2DM). METHOD: Cross-sectional data were obtained from 2786 patients with T2DM recruited from a Chinese diabetes registry. Patients' records were reviewed to obtain data pertaining to age, sex, Body Mass Index (BMI), marital status, level of education, smoking status, duration of diabetes mellitus, use of insulin, and presence of additional illnesses...
October 26, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27056608/a-double-blind-randomized-placebo-controlled-dose-frequency-study-of-intravenous-ketamine-in-patients-with-treatment-resistant-depression
#12
RANDOMIZED CONTROLLED TRIAL
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, Peter De Boer, Kimberly Cooper, Pilar Lim, Christine Pinter, James W Murrough, Gerard Sanacora, Richard C Shelton, Benji Kurian, Andrew Winokur, Maurizio Fava, Husseini Manji, Wayne C Drevets, Luc Van Nueten
OBJECTIVE: Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant depression. METHOD: In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0...
August 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27282362/efficacy-and-safety-of-antidepressants-added-to-antipsychotics-for-schizophrenia-a-systematic-review-and-meta-analysis
#13
REVIEW
Bartosz Helfer, Myrto T Samara, Maximilian Huhn, Elisabeth Klupp, Claudia Leucht, Yikang Zhu, Rolf R Engel, Stefan Leucht
OBJECTIVE: The authors examined the safety and efficacy of antidepressants added to antipsychotic drugs in the treatment of schizophrenia. METHOD: Multiple databases and previous publications were searched through June 2015 to identify all randomized controlled trials of any add-on antidepressants compared with placebo or no-treatment in schizophrenia. Depressive and negative symptoms (primary outcomes), overall symptoms, positive symptoms, side effects, exacerbation of psychosis, and responder rates were examined...
September 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28068463/long-term-acute-phase-treatment-with-antidepressants-8-weeks-and-beyond-a-systematic-review-and-meta-analysis-of-randomized-placebo-controlled-trials
#14
Jonathan Henssler, Mona Kurschus, Jeremy Franklin, Tom Bschor, Christopher Baethge
OBJECTIVE: In clinical practice, acute antidepressant treatment is often applied for several months until remission is achieved. However, data on treatment outcomes beyond 8 weeks are sparse and no systematic review exists to date. This study aims at assessing efficacy and tolerability of antidepressants compared to placebo in acute treatment at and beyond 8 weeks. DATA SOURCES: MEDLINE, Embase, PsycINFO, and CENTRAL databases were systematically searched through March 2014 using generic terms for depressive and affective disorders combined with generic terms for individual drugs and placebo...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27929611/switching-the-antidepressant-after-nonresponse-in-adults-with-major-depression-a-systematic-literature-search-and-meta-analysis
#15
Tom Bschor, Hannah Kern, Jonathan Henssler, Christopher Baethge
OBJECTIVE: Nonresponders to antidepressant monotherapy during acute treatment of major depression are often switched to a new antidepressant. The objective of this meta-analysis was to compare the efficacy of switching to a new antidepressant with continuation of the first antidepressant. DATA SOURCES: PubMed, Embase, PsycINFO, and Cochrane Central Register of Controlled Trials (CENTRAL) databases and additional sources were systematically searched independently by 2 authors up to March 2015 without language limitations...
December 6, 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27908897/cortisol-as-a-predictor-of-psychological-therapy-response-in-depressive-disorders-systematic-review-and-meta-analysis
#16
REVIEW
Susanne Fischer, Rebecca Strawbridge, Andres Herane Vives, Anthony J Cleare
BACKGROUND: Many patients with depressive disorders demonstrate resistance to psychological therapy. A frequent finding is hypothalamic-pituitary-adrenal (HPA) axis alterations. As cortisol is known to modulate cognitive processes, those patients may be less likely to profit from psychological therapy. AIMS: To conduct a systematic review and meta-analysis on cortisol as a predictor of psychological therapy response. METHOD: The Cochrane Library, EMBASE, MEDLINE and PsycINFO databases were searched...
February 2017: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/27784055/toward-an-evidence-based-operational-definition-of-treatment-resistant-depression-when-enough-is-enough
#17
Charles R Conway, Mark S George, Harold A Sackeim
No abstract text is available yet for this article.
January 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/27726982/placebo-response-rates-in-antidepressant-trials-a-systematic-review-of-published-and-unpublished-double-blind-randomised-controlled-studies
#18
Toshi A Furukawa, Andrea Cipriani, Lauren Z Atkinson, Stefan Leucht, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Anna Chaimani, Georgia Salanti
BACKGROUND: Previous studies have shown that placebo response rates in antidepressant trials have been increasing since the 1970s. However, these studies have been based on outdated or limited datasets and have used inappropriate statistical methods. We did a systematic review of placebo-controlled randomised controlled trials of antidepressants to examine associations between placebo-response rates and study and patient characteristics. METHODS: In this systematic review, we searched for published and unpublished double-blind randomised placebo-controlled trials of first-generation and second-generation antidepressants for acute treatment of major depression in adults (update: Jan 8, 2016)...
November 2016: Lancet Psychiatry
https://www.readbyqxmd.com/read/20331548/mindfulness-based-treatments-for-co-occurring-depression-and-substance-use-disorders-what-can-we-learn-from-the-brain
#19
Judson A Brewer, Sarah Bowen, Joseph T Smith, G Alan Marlatt, Marc N Potenza
Both depression and substance use disorders represent major global public health concerns and are often co-occurring. Although there are ongoing discoveries regarding the pathophysiology and treatment of each condition, common mechanisms and effective treatments for co-occurring depression and substance abuse remain elusive. Mindfulness training has been shown recently to benefit both depression and substance use disorders, suggesting that this approach may target common behavioral and neurobiological processes...
October 2010: Addiction
https://www.readbyqxmd.com/read/27508501/the-safety-tolerability-and-risks-associated-with-the-use-of-newer-generation-antidepressant-drugs-a-critical-review-of-the-literature
#20
André F Carvalho, Manu S Sharma, André R Brunoni, Eduard Vieta, Giovanni A Fava
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later...
2016: Psychotherapy and Psychosomatics
label_collection
label_collection
2805
1
2
2016-08-17 21:57:36
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"